- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
A Closer Look at IL-17 Inhibitors in Psoriasis : Episode 3
Opinion
Video
Clinical Attributes of IL-17 Inhibitors in Psoriasis
Panelists discuss how IL-17 inhibitors are biologics that target the inflammatory cytokine IL-17 pathway. They demonstrate rapid onset of action, with measurable improvement in most patients within 2 to 4 weeks and peak efficacy by 12 to 16 weeks. They achieve high rates of skin clearance in psoriasis patients and maintain efficacy with long-term use.
Video Player is loading.
Video content above is prompted by the following:
What are some of the clinical attributes of IL-17 inhibitors? How quickly do they work in their onset of action, and how do they impact skin clearance?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Current Unmet Needs and Emerging Solutions in Atopic Dermatitis Management
Implementation Factors Affecting Ruxolitinib Adoption in Pediatric Dermatology Practice
Regulatory Challenges and Clinical Differentiators for Pediatric Atopic Dermatitis Treatments
Evaluating the Impact of Topical JAK Inhibitors on Pediatric Atopic Dermatitis Guidelines
The Future of Pediatric Atopic Dermatitis Treatment and Emerging Therapies
What Lies Ahead for GPP Diagnosis and Management
Case 3: High-Risk Patient with GPP Treatment Approach
Larry Eichenfield, MD: Safety, Convenience, and Future Role of Icotrokinra in Treating Adolescent Psoriasis
Future Directions for IL-17 Inhibitors in Psoriasis and Psoriatic Arthritis Care
Future Perspectives: Can Innovative Topical Therapies Like Ruxolitinib Reduce Systemic Treatment Dependency in Pediatric AD?
Related Content
